Abstract: Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.

Abstract: A rotary valve for an adsorption heat pump may include a cylindrical valve body, arranged rotatably about a central axis in a predetermined rotation direction with an outer covering and two front plates. A plurality of counter-directional high temperature connections may be arranged on the outer covering for connecting a high temperature heat source. A plurality of counter-directional medium temperature connections may be arranged on the outer covering for connecting a medium temperature heat sink. A plurality of sorption module connections may be arranged on the front plates for connecting a plurality of corresponding sorption modules. A duct system may pass through the valve body for directing a fluid, and a throttle, integrated into the valve body, may be included for constricting a flow cross-section at a throttle site of the duct system. The duct system may include open ducts and closed ducts.

Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl

Abstract: A cooling device for a battery system may include at least two battery units. The cooling device may include at least a first and a second cooling plate able to be flowed through respectively by a coolant. The first and second cooling plate may be arranged respectively for thermal coupling with a respective battery unit. The first and second cooling plate each may include a first fluid inlet, which is connected fluidically with a first fluid outlet via a first fluid duct extending along an extent direction, and a second fluid inlet, which is connected fluidically with a second fluid outlet via a second fluid duct extending along the extent direction.

Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.

Abstract: The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-administration of a sulfated glycosaminoglycan and a hyaluronidase.

Abstract: A heat exchanger may include a plate, a seal and a cover. The plate may have at least two receiving grooves having a respective groove base, an intermediate region disposed in a plane between a plurality of rim holes, and a ramp extending between the intermediate region and the respective groove base of the at least two receiving grooves. The seal extends in the at least two receiving grooves. The ramp may be rounded at a transition to the receiving grooves with a first radius and at a transition to the intermediate region with a second radius, and the ramp may be inclined between 20°<?<65° relative to the intermediate region or has an S-shaped progression. An inflection point of the plate may be arranged in a region from 10% to 80% of a height difference between the intermediate region and the respective groove base.

Abstract: A method for producing an intake module may include providing a housing and at least one intercooler arranged therein; forming at least two housing parts via injection molding from plastic; inserting at least one intercooler into at least one of the housing parts; wherein the housing parts, with at least one intercooler inserted therein, are welded together to form the housing; and wherein the intercooler has contact points to at least two of the housing parts.

Abstract: A heat exchanger for an exhaust gas cooler may include a substantially fluid-tight housing for conducting a first mass flow. At least one heat-permeable tube may extend in the housing for conducting a second mass flow. The housing and an outer surface of the at least one tube may define at least two parallel flow paths for the first mass flow. A plate at least partially containing the at least one tube may delimit the at least two flow paths on a face end. A connection may be arranged in a region of the plate for introducing the first mass flow into the housing. The outer surface of the at least one tube may have an elevation configured to distribute the first mass flow substantially uniformly after entering the housing and divide the first mass flow substantially uniformly among the at least two flow paths.

Abstract: The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan.

Abstract: A heat exchanger for a motor vehicle is provided having at least one block formed by tubes arranged parallel to one another and by fins arranged between the tubes. The tubes form multiple first flow ducts through which a first fluid can flow. The regions between the tubes form multiple second flow ducts through which a second fluid can flow around the tubes. The heat exchanger also has a first collecting box with a first fluid port and a second collecting box with a second fluid port. The first flow ducts are in fluid communication with a first cooling circuit via the first fluid port, the second fluid port, and the collecting boxes. The first collecting box or the second collecting box also has a third fluid port that, together with its respective collecting box and further fluid port, are in fluid communication with a second cooling circuit.

Abstract: An evaporator heat exchanger for evaporating a liquid working medium may include a housing, in which at least one first flow channel for conducting the working medium and at least one second flow channel for conducting a gas may be arranged, where heat may be transferable from the gas to the working medium. The evaporator heat exchanger may also include a plurality of cover plates and a profiled fluid plate arranged in between two of the cover plates. The at least two cover plates and the profiled fluid plate may form the at least one first flow channel, and at the same time may delimit at least one of at least one leakage channel and a leakage space that is separated from the at least one first flow channel and at least one second flow channel.

Abstract: The invention relates to a system for using the waste heat of an internal combustion engine by means of the Clausius-Rankine cycle, wherein an incorporation of an operating medium into the combustion air fed to the combustion engine due to lack of sealing or a leak at the evaporator heat exchanger is substantially ruled out.

Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.

Abstract: A heat exchanger component of a temperature control system of an electrical energy store may include a carrier material and at least two layers. The at least two layers may include a first layer composed of an electrically insulating material and a second layer that may facilitate temperature control via at least one of cooling and heating the electrical energy store.

Abstract: A heat exchanger component of a temperature control system of an electrical energy store may include a carrier material and at least two layers. The at least two layers may include a first layer composed of an electrically insulating material and a second layer that may facilitate temperature control via at least one of cooling and heating the electrical energy store.

Abstract: An air supply system for supplying fresh air to at least one combustion chamber of an internal combustion engine may include a housing having a fresh air path and a lateral introduction opening. A charge-air cooler may be instertable into the housing via the introduction opening along an introduction direction. The charge-air cooler may be arranged in the housing and the fresh air path may extend through the charge air cooler. The charge air cooler may include an outer end region closing the introduction opening. The outer end region of the charge-air cooler may be secured to the housing.

Abstract: The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA.

Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasm